CT-P13 is a biosimilar to infliximab, a chimeric IgG1 monoclonal antibody that binds and neutralizes soluble and transmembrane TNF-α, blocking TNFR1/TNFR2 signaling. It can mediate ADCC and CDC and induce apoptosis of TNF-expressing immune cells, leading to downregulation of NF-κB–driven proinflammatory cytokines, chemokines, and adhesion molecules and reduced inflammation.